BerandaROIV • NASDAQ
add
Roivant Sciences Ltd
$27,80
Setelah Jam Perdagangan Normal:(0,00%)0,00
$27,80
Tutup: 19 Mar, 16.02.49 GMT-4 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$27,80
Rentang hari
$27,17 - $27,93
Rentang tahun
$8,73 - $30,33
Kapitalisasi pasar
19,90Â M USD
Volume Rata-Rata
6,83Â jt
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Dalam berita
Keuangan
Laporan Laba Rugi
Pendapatan
Penghasilan bersih
| (USD) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 2,00Â jt | -77,83% |
Biaya operasional | 175,05Â jt | 32,27% |
Penghasilan bersih | -265,89Â jt | -256,98% |
Margin laba bersih | -13,30Â rb | -808,17% |
Penghasilan per saham | -0,24 | -20,57% |
EBITDA | -338,44Â jt | -29,41% |
Tarif pajak efektif | -8,04% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 4,53Â M | -11,98% |
Total aset | 5,23Â M | -9,79% |
Total liabilitas | 251,14Â jt | -2,04% |
Total ekuitas | 4,97 M | — |
Saham yang beredar | 715,70 jt | — |
Harga terhadap nilai buku | 4,62 | — |
Tingkat pengembalian aset | -16,48% | — |
Tingkat pengembalian modal | -16,98% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Penghasilan bersih | -265,89Â jt | -256,98% |
Kas dari operasi | -196,48Â jt | 5,20% |
Kas dari investasi | 109,47Â jt | -75,89% |
Kas dari pembiayaan | 328,19Â jt | 220,24% |
Perubahan kas bersih | 241,61Â jt | 988,44% |
Arus kas bebas | -88,76Â jt | 70,76% |
Tentang
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel. Wikipedia
CEO
Didirikan
7 Apr 2014
Situs
Karyawan
750
